Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691054 · ClinicalTrials.gov registry record · Phase 2
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
A Phase 2 study of Pancreatic Cancer, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00691054 is a Phase 2 study of Pancreatic Cancer that has completed, run by University of Miami. The registered enrollment target is 20 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00691054, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with locally advanced or metastatic pancreatic cancer that did not respond to first-line therapy with gemcitabine.
Conditions Studied
Interventions
- DRUG Abraxane
Study Locations (2)
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami - Miami
Other
- Johns Hopkins Singapore International Medical Centre - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691054
The ClinicalTrials.gov registry entry for NCT00691054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Abraxane is the first listed.
NCT00691054 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT00691054 about?
NCT00691054 is a clinical study titled "Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy". RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabil...
What is the current status of trial NCT00691054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2012-12.
What conditions does trial NCT00691054 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00691054?
The interventions under investigation include: Abraxane (DRUG).
Who is sponsoring clinical trial NCT00691054?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00691054 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.